July 16, 2024 -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798. “The promise of FXR314 is strong and I encourage investors to review our newest presentation,” said Keith Murphy, Executive Chairman. “As mergers and acquisitions continue to be strong in inflammatory bowel disease, highlighted by the Lilly acquisition of Morphic for $3.2B after strong Phase 2a results, we are encouraged by our progress and our near-term opportunity to show the value of FXR314 in IBD in our own Phase 2a trial. Completing the trial swiftly is important for our investors and for patients, as we expect to demonstrate activity of FXR314 that matches the strong results we’ve seen in a highly predictive preclinical animal model, as well as the strong data demonstrating the impact of FXR314 to relieve disease aspects in our 3d human models of ulcerative colitis and Crohn’s disease.” Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com. The content above comes from the network. if any infringement, please contact us to modify.